

# Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent

**Deliverability of EluNIR™ stent in complex patient anatomy demonstrated during first commercial cases at Columbia University Medical Center and Piedmont Heart Institute**



*The EluNIR™ stent system is designed to help clinicians easily deliver this new DES in highly complex anatomy and disease and offers a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market.*

**DUBLIN, Ohio, January 11, 2018** — Cordis, a Cardinal Health company, and Medinol today announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States were performed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City and the Piedmont Heart Institute in Atlanta.

"Our first patient cases with the EluNIR™ stent went perfectly and we are enthusiastic about the overall performance including the uniform vessel coverage and the delivery system with the metallic spring tip, which is unlike any other product in the market," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at the New York-Presbyterian Hospital/Columbia University Medical Center. "I have been following Medinol for over 20 years and am excited to see yet another one of the company's innovative products launch in the U.S. market."

The EluNIR™ stent was approved for the treatment of patients with narrowing or blockages to their coronary arteries and is now being distributed to cath labs in the U.S. by Cordis. The EluNIR™ stent system is designed to help clinicians easily deliver this new DES in highly complex anatomy and disease and offers a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market.

"The physicians and staff at Columbia and Piedmont have played pivotal roles in the evolution of the EluNIR™ stent," said Dr. Yoram Richter, chief scientific officer at Medinol. "We are honored to have the first commercial cases with EluNIR™ performed at such notable institutions. This event marks another step in Medinol's legacy, which has continued to stretch the limits of innovation, starting with our NIR stent in 1996."

Cardinal Health and Medinol entered into a long-term distribution agreement that gives Cordis, Cardinal Health's interventional vascular business, the rights to sell Medinol's coronary stent portfolio, which now includes the EluNIR™ DES and NIRxcell™, a cobalt-chromium bare metal stent (BMS), in the U.S.

"We are confident that the novel stent and delivery system of the EluNIR™ DES will offer ease of delivery, especially in highly complex cases," said Luis Davila, vice president of R&D at Cordis. "Cordis is committed to bringing new technologies, like EluNIR™, to the market to provide even more treatment options for clinicians and their patients affected by coronary artery disease."

## **About Percutaneous Coronary Intervention (PCI)**

PCI is a nonsurgical procedure that often uses a catheter to place a stent to open blocked coronary arteries caused by coronary artery disease, which is a common type of cardiovascular disease. Cardiovascular disease

is the leading global cause of death, accounting for more than 17.3 million deaths per year in 2013, a number that is expected to grow to more than 23.6 million by 2030. In the U.S., about 2,200 people die of cardiovascular disease each day, an average of one death every 40 seconds. <sup>[i]</sup>

### **About Medinol**

Medinol was founded in 1992 by Drs. Judith and Kobi Richter. It's a privately held company with offices in the U.S. and Israel and employs more than 300 people. Medinol has an extensive patent portfolio, including a long, established history in the coronary stent market over the past 20 years. The unique design of its products, along with its rigorous standards of manufacturing and safety, makes Medinol a leading developer in this space. All Medinol's cardiovascular intervention solutions are manufactured in-house using its proprietary QualitySurface™ manufacturing technology. This unique manufacturing method enables Medinol to conduct strict and automated quality control on each individual stent, ensuring consistently exceptional product quality and safety. Medinol's EluNIR™ DES was developed to offer clinicians a new generation DES with an optimized stent and delivery system. With more than two million stents delivered globally to date, Medinol's cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results.

### **About Cardinal Health**

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #15 on the *Fortune* 500. For more information, visit [cardinalhealth.com](http://cardinalhealth.com), follow [@CardinalHealth](https://twitter.com/CardinalHealth) on Twitter and connect on LinkedIn at [linkedin.com/company/cardinal-health](https://www.linkedin.com/company/cardinal-health).

[i] [https://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm\\_491265.pdf](https://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm_491265.pdf)

For further information: Courtney Tobin (614) 553-3539 [courtney.tobin@cardinalhealth.com](mailto:courtney.tobin@cardinalhealth.com)

---

[http://cardinalhealth.mediaroom.com/EluNIR\\_DES](http://cardinalhealth.mediaroom.com/EluNIR_DES)